头颈部鳞状细胞癌（SCCHN）中的预测性生物标志物与表皮生长因子受体（EGFR）抑制剂 - Suppr

Suppr

超能文献

Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN).

作者信息

Vigneswara V, Kong A

机构信息

Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.

出版信息

Ann Oncol. 2018 Apr 1;29(4):794-796. doi: 10.1093/annonc/mdy065.

DOI:10.1093/annonc/mdy065

PMID:29444313

Abstract

摘要

相似文献

Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN).头颈部鳞状细胞癌（SCCHN）中的预测性生物标志物与表皮生长因子受体（EGFR）抑制剂

Ann Oncol. 2018 Apr 1;29(4):794-796. doi: 10.1093/annonc/mdy065.

Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.阿法替尼在体外和体内对头颈部鳞状细胞癌细胞系的疗效。

Target Oncol. 2015 Dec;10(4):501-8. doi: 10.1007/s11523-014-0353-6. Epub 2015 Jan 6.

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.肺鳞状细胞癌和头颈部鳞状细胞癌中表皮生长因子受体抑制的生物学和反应模式。

Cancer Treat Rev. 2017 Mar;54:43-57. doi: 10.1016/j.ctrv.2017.01.003. Epub 2017 Jan 17.

Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.针对介导头颈部鳞状细胞癌对抗表皮生长因子受体（EGFR）治疗耐药性的信号通路

Expert Rev Anticancer Ther. 2016 Aug;16(8):847-58. doi: 10.1080/14737140.2016.1202116. Epub 2016 Jul 11.

Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.局部晚期头颈部鳞状细胞癌的当前治疗选择及研究性靶向治疗概述

Am J Clin Oncol. 2016 Aug;39(4):396-406. doi: 10.1097/COC.0000000000000283.

Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.阿法替尼的临床前和临床开发：重点关注乳腺癌和头颈部鳞状细胞癌。

Future Oncol. 2014 Jan;10(1):21-40. doi: 10.2217/fon.13.244.

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.阿法替尼同时靶向 EGFR、HER2 和 HER4，克服了头颈部鳞状细胞癌细胞系中内在和获得性西妥昔单抗耐药性。

Mol Oncol. 2018 Jun;12(6):830-854. doi: 10.1002/1878-0261.12197. Epub 2018 May 1.

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).在一项 EORTC 窗口术前研究中评估阿法替尼在头颈部鳞状细胞癌（SCCHN）患者中的活性和安全性。

Ann Oncol. 2018 Apr 1;29(4):985-991. doi: 10.1093/annonc/mdy013.

Afatinib in squamous cell carcinoma of the head and neck.阿法替尼治疗头颈部鳞状细胞癌。

Expert Opin Pharmacother. 2016 Jun;17(9):1295-301. doi: 10.1080/14656566.2016.1183647. Epub 2016 May 19.

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.阿法替尼对比甲氨蝶呤用于铂类治疗后进展的复发性或转移性头颈部鳞状细胞癌患者的二线治疗（LUX-Head & Neck 1）：一项开放标签、随机、III 期研究。

Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16.

引用本文的文献

Current trends of targeted therapy for oral squamous cell carcinoma.口腔鳞状细胞癌靶向治疗的现状。

J Cancer Res Clin Oncol. 2022 Sep;148(9):2169-2186. doi: 10.1007/s00432-022-04028-8. Epub 2022 May 2.

Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis.从系统药物基因组学数据分析中挖掘头颈部癌症的药物再利用候选物。

Sci Rep. 2021 Dec 14;11(1):23933. doi: 10.1038/s41598-021-03418-1.

Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck.头颈部局部晚期和复发性转移性鳞状细胞癌中表皮生长因子受体（EGFR）抑制的当前现状与未来考量

Cancers (Basel). 2021 Jul 15;13(14):3545. doi: 10.3390/cancers13143545.

Hsa_circ_0005379 regulates malignant behavior of oral squamous cell carcinoma through the EGFR pathway.Hsa_circ_0005379 通过 EGFR 通路调节口腔鳞状细胞癌的恶性行为。

BMC Cancer. 2019 Apr 29;19(1):400. doi: 10.1186/s12885-019-5593-5.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验